Cellular Biomedicine Group Inc., of Shanghai, said it closed two private placement transactions selling an aggregate of 1.2 million shares to selected key executives and private investors at $12 each, for total gross proceeds of approximately $14.5 million. The company intends to use the proceeds to fund clinical trials, invest in new product development and expand their research and development programs.